10 Best Immunotherapy Stocks to Buy Now

6. argenx SE (NASDAQ:ARGX)

Number of Hedge Fund Holders: 52

argenx SE (NASDAQ:ARGX) is a global immunology company developing treatments for autoimmune diseases. By partnering with leading researchers, it is translating groundbreaking discoveries into new antibody-based medicines. The company’s recent FDA approval for VYVGART Hytrulo in CIDP showcases its leadership in autoimmune therapies.

According to the Q2 2024 results, argenx SE (NASDAQ:ARGX)’s net sales rose to $477.6 million, and the company turned a profit after reporting losses a year ago. According to its current operating plans, argenx SE (NASDAQ:ARGX) has revised its cash burn outlook and now projects using less than $500 million in net cash in 2024 for expected operating costs, working capital, and capital expenditures.

With the recent FDA approval and encouraging results, analysts are bullish on this stock and have given it an average rating of Strong Buy. Here’s what TimesSquare Capital Management said about argenx SE (NASDAQ:ARGX) in its Q2 2024 investor letter:

“Our preferences among Health Care stocks are those companies providing novel therapies for unmet needs that deserve premium pricing, or specialized service providers. One example was Argenx SE (NASDAQ:ARGX), a biotechnology developer of antibody treatments for autoimmune disorders. This quarter the company received unrestricted approval from the FDA for its VYVGART Hytrulo to treat chronic inflammatory demyelinating polyneuropathy (CIDP). Not only did that extend argenx’s VYVGART treatment to a new indication—CIDP causes swelling and inflammation of peripheral nerves that leads to a loss of strength or sensations in arms and legs, but this new use has significantly higher pricing for argenx. That gave its shares a 9% lift this quarter.”